Genmab dominates tivdak market as ADC competition tightens

The tivdak market is highly concentrated, with Genmab A/S holding 78% of global sales in 2024 and Genmab and Pfizer together accounting for all revenue. The Business Research Company says targeted antibody-drug conjugates and cervical cancer treatment demand are driving the market outlook through 2035.

Why it matters: - The tivdak market is small but tightly controlled, which raises the stakes for clinical innovation, manufacturing scale and regulatory execution. - Demand is tied to recurrent and metastatic cervical cancer treatment, where targeted antibody-drug conjugate therapy is shaping care options and competitive strategy. - Market concentration leaves few winners, making partnerships and commercialization strength especially important for future share gains.

What happened: - The Business Research Company released its Tivdak Market Report 2026 covering market size, trends and a global forecast for 2026-2035. - Genmab A/S led global tivdak sales in 2024 with a 78% market share. - Pfizer Inc. held the remaining 22% share, giving the top two companies 100% of market revenue in 2024. - Genmab launched tivdak, or tisotumab vedotin, in December 2025 as an intravenous antibody-drug conjugate for adults with recurrent or metastatic cervical cancer after prior anti-cancer treatment. - The report is available through the full market report and a free sample.

The details: - The report says the market is dominated by biotechnology companies and oncology-focused pharmaceutical manufacturers. - Competition is centered on antibody-drug conjugate innovation, biologics development, clinical pipeline advancement, precision treatment technologies and oncology commercialization infrastructure. - The report says major barriers include complex biologics development, stringent oncology approval pathways, specialized manufacturing and extensive clinical validation. - Major raw material suppliers listed in the report include Lonza Group AG, FUJIFILM Diosynth Biotechnologies, AGC Biologics, Samsung Biologics, Catalent Inc., Thermo Fisher Scientific Inc. and WuXi Biologics. - Other suppliers named include Recipharm AB, Evonik Industries AG, Merck KGaA, Cytiva, Ajinomoto Bio-Pharma Services, Boehringer Ingelheim BioXcellence, CordenPharma International, Siegfried Holding AG, Piramal Pharma Solutions, Asymchem Laboratories Inc., AbbVie Contract Manufacturing, Cambrex Corporation, EuroAPI and Charles River Laboratories International Inc. - Major wholesalers and distributors named in the report include Morris & Dickson Co. LLC, Anda Inc., FFF Enterprises Inc., CuraScript SD, Oncology Supply, Besse Medical, Medline Industries LP, Specialty Networks LLC, ASD Healthcare, McKesson Specialty Health, Cardinal Health Specialty Pharmaceutical Distribution, BioCareSD LLC, McKesson Plasma and Biologics, CVS Specialty Inc., Accredo Health Group Inc., Optum Specialty Pharmacy and CarelonRx Specialty. - Major end users listed include Dana-Farber Cancer Institute, Stanford Health Care, Cedars-Sinai Medical Center, Mount Sinai Health System, Northwestern Memorial Hospital, Johns Hopkins Hospital, Mass General Brigham, UCLA Health, City of Hope, The Royal Marsden NHS Foundation Trust, Apollo Hospitals, Fortis Healthcare, Max Healthcare, Manipal Hospitals, HCA Healthcare and Baptist Health System.

Between the lines: - The report frames ADCs as the key innovation lane because they can improve treatment precision and reduce systemic toxicity compared with broader cancer therapies. - Genmab’s lead suggests the market currently rewards companies with both drug-development expertise and commercialization reach. - The concentration also signals that new entrants face a difficult path unless they can bring differentiated clinical data or stronger distribution access. - The report’s strategy list points to collaboration, clinical research and regulatory approvals as the main levers for expanding access and defending position.

What's next: - The report expects lifecycle management, clinical innovation and broader oncology care-network expansion to shape competition over the forecast period. - Continued development of targeted biologics and new ADC programs could create additional treatment options for cervical cancer patients. - Stakeholders are likely to focus on partnership opportunities, manufacturing quality and market-access execution as the category evolves.

The bottom line: - Genmab and Pfizer control the tivdak market today, and future growth will depend on who can pair ADC innovation with the best oncology commercialization strategy.